Citations (124)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Srinath Innani, Yashika Tomar, Vikas Rana & Gautam Singhvi. (2023) Navigating the landscape of psoriasis therapy: novel targeted pathways and emerging trends. Expert Opinion on Therapeutic Targets 0:0, pages 1-10.
Read now
Read now
Megan Mosca, Julie Hong, Edward Hadeler, Marwa Hakimi, Wilson Liao & Tina Bhutani. (2021) The Role of IL-17 Cytokines in Psoriasis. ImmunoTargets and Therapy 10, pages 409-418.
Read now
Read now
K. B. Garbutcheon-Singh, N. Carnt, U. Pattamatta, C. Samarawickrama, A. White & V. Calder. (2019) A Review of the Cytokine IL-17 in Ocular Surface and Corneal Disease. Current Eye Research 44:1, pages 1-10.
Read now
Read now
Suresh Kumar Karri & A. Sheela. (2017) Potential route of Th17/Treg cell dynamics in targeting type 1 diabetes and rheumatoid arthritis: an autoimmune disorder perspective. British Journal of Biomedical Science 74:1, pages 8-15.
Read now
Read now
M. Galluzzo, S. D’adamio, L. Bianchi & M. Talamonti. (2016) Brodalumab for the treatment of psoriasis. Expert Review of Clinical Immunology 12:12, pages 1255-1271.
Read now
Read now
Andrea Chiricozzi, Marco Romanelli, Rosita Saraceno & Tiago Torres. (2016) No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opinion on Drug Safety 15:12, pages 1653-1659.
Read now
Read now
Yael Renert-Yuval & Emma Guttman-Yassky. (2016) A novel therapeutic paradigm for patients with extensive alopecia areata. Expert Opinion on Biological Therapy 16:8, pages 1005-1014.
Read now
Read now
Andrea Chiricozzi, Rosita Saraceno, Lucia Novelli, Monika Fida, Francesco Caso, Raffaele Scarpa, Luisa Costa, Roberto Perricone, Marco Romanelli, Sergio Chimenti & Maria Sole Chimenti. (2016) Small molecules and antibodies for the treatment of psoriasis: a patent review (2010–2015). Expert Opinion on Therapeutic Patents 26:7, pages 757-766.
Read now
Read now
Tarannum Jaleel, Craig Elmets, Allison Weinkle, Sama Kassira & Boni Elewski. (2016) Secukinumab (AIN-457) for the treatment of Psoriasis. Expert Review of Clinical Pharmacology 9:2, pages 187-202.
Read now
Read now
Duo Li, Bin Guo, Haijing Wu, Lina Tan, Christopher Chang & Qianjin Lu. (2015) Interleukin-17 in systemic lupus erythematosus: A comprehensive review. Autoimmunity 48:6, pages 353-361.
Read now
Read now
Andrea Chiricozzi, Sara Faleri, Rosita Saraceno, Luca Bianchi, Oreste Buonomo, Sergio Chimenti & Maria Sole Chimenti. (2015) Tofacitinib for the treatment of moderate-to-severe psoriasis. Expert Review of Clinical Immunology 11:4, pages 443-455.
Read now
Read now
Ann Sophie Lønnberg, Claus Zachariae & Lone Skov. (2014) Targeting of interleukin-17 in the treatment of psoriasis. Clinical, Cosmetic and Investigational Dermatology 7, pages 251-259.
Read now
Read now
Fatemeh Rajaii, Allison N McCoy & Terry J Smith. (2014) Cytokines as villains and potential therapeutic targets in thyroid-associated ophthalmopathy: from bench to bedside. Expert Review of Ophthalmology 9:3, pages 227-234.
Read now
Read now
Andreas Willerslev-Olsen, Ivan V Litvinov, Simon M Fredholm, David L Petersen, Nina A Sibbesen, Robert Gniadecki, Qian Zhang, Charlotte M Bonefeld, Mariusz A Wasik, Carsten Geisler, Youwen Zhou, Anders Woetmann, Denis Sasseville, Thorbjørn Krejsgaard & Niels Ødum. (2014) IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF). Cell Cycle 13:8, pages 1306-1312.
Read now
Read now
Maeve Lynch, Brian Kirby & Richard B Warren. (2014) Treating moderate to severe psoriasis – best use of biologics. Expert Review of Clinical Immunology 10:2, pages 269-279.
Read now
Read now
Aikaterini Kyriakou, Aikaterini Patsatsi & Dimitrios Sotiriadis. (2013) Biologic agents in nail psoriasis: efficacy data and considerations. Expert Opinion on Biological Therapy 13:12, pages 1707-1714.
Read now
Read now
Articles from other publishers (108)
Andrey Bakulev, Olga Pritulo, Zhanna Kuntsevich, Alkes Khotko, Aastasia Yunovidova, Pavel Gorognichev, Oleg Ziganshin, Natalya Rudneva, Evgenya Bildyuk, Tatyana Repina, Valentina Dudko & Marya Maksimova. (2023) Efficacy and safety of netakimab therapy in patients with moderate and severe psoriasis in real clinical practice. Vestnik dermatologii i venerologii.
Crossref
Crossref
Eva Reali, Cristiana Caliceti, Antonello Lorenzini & Paola Rizzo. (2023) The Use of Microbial Modifying Therapies to Prevent Psoriasis Exacerbation and Associated Cardiovascular Comorbidity. Inflammation.
Crossref
Crossref
Qian Xiao, Joseph Mears, Aparna Nathan, Kazuyoshi Ishigaki, Yuriy Baglaenko, Noha Lim, Laura A. Cooney, Kristina M. Harris, Mark S. Anderson, David A. Fox, Dawn E. Smilek, James G. Krueger & Soumya Raychaudhuri. (2023) Immunosuppression causes dynamic changes in expression QTLs in psoriatic skin. Nature Communications 14:1.
Crossref
Crossref
Antonio Olveira, Salvador Augustin, Salvador Benlloch, Javier Ampuero, Jorge Alonso Suárez-Pérez, Susana Armesto, Eva Vilarrasa, Isabel Belinchón-Romero, Pedro Herranz, Javier Crespo, Francisco Guimerá, Lara Gómez-Labrador, Víctor Martín & José Manuel Carrascosa. (2023) The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease. Life 13:2, pages 419.
Crossref
Crossref
Anaïs Makos, J. H. Kuiper, O. Kehoe & R. Amarasena. (2022) Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors. Inflammopharmacology 31:1, pages 77-87.
Crossref
Crossref
Yun-Juan Nie, Shuo-Hua Wu, Ying-Hua Xuan & Gen Yan. (2022) Role of IL-17 family cytokines in the progression of IPF from inflammation to fibrosis. Military Medical Research 9:1.
Crossref
Crossref
Jiajia Fu, Yan Huang, Ting Bao, Chengcheng Liu, Xi Liu & Xueping Chen. (2022) The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A. Journal of Neuroinflammation 19:1.
Crossref
Crossref
Meihui Cheng, Jingwen Xu, Kaiyun Ding, Jing Zhang, Wei Lu, Jiansheng Liu, Jiahong Gao, Kishore R. Alugupalli & Hongqi Liu. (2022) Attenuation of relapsing fever neuroborreliosis in mice by IL-17A blockade. Proceedings of the National Academy of Sciences 119:42.
Crossref
Crossref
Yun Zhou, Lixian Zhong, Lianli Shen, Sisi Chen, Qiuting Zeng, Leizhen Lai & Shaohui Tang. (2022) Psoriasis and medical ramifications: A comprehensive analysis based on observational meta-analyses. Frontiers in Medicine 9.
Crossref
Crossref
Eric R. Goedken, Maria A. Argiriadi, Justin D. Dietrich, Andrew M. Petros, Navasona Krishnan, Sanjay C. Panchal, Wei Qiu, Haihong Wu, Haizhong Zhu, Ashley M. Adams, Pierre M. Bodelle, Lucas Goguen, Paul L. Richardson, Peter F. Slivka, Myron Srikumaran, Anup K. Upadhyay, Bainan Wu, Russell A. Judge, Anil Vasudevan, Sujatha M. Gopalakrishnan, Philip B. Cox, Vincent S. Stoll & Chaohong Sun. (2022) Identification and structure-based drug design of cell-active inhibitors of interleukin 17A at a novel C-terminal site. Scientific Reports 12:1.
Crossref
Crossref
Lanmei Lin, Yilun Wang, Xiaonian Lu, Tianxiao Wang, Qunyi Li, Runnan Wang, Jinfeng Wu, Jinhua Xu & Juan Du. (2022) The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis. Frontiers in Pharmacology 13.
Crossref
Crossref
Yamin Shu, Yufeng Ding, Yanxin Liu, Pan Wu, Xucheng He & Qilin Zhang. (2022) Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System. Frontiers in Pharmacology 13.
Crossref
Crossref
Yan Wang, Jinxin Zang, Chen Liu, Zhongrui Yan & Dongmei Shi. (2022) Interleukin-17 Links Inflammatory Cross-Talks Between Comorbid Psoriasis and Atherosclerosis. Frontiers in Immunology 13.
Crossref
Crossref
Soh Yamazaki, Naohiro Inohara, Masaki Ohmuraya, Yousuke Tsuneoka, Hideo Yagita, Takaharu Katagiri, Takashi Nishina, Tetuo Mikami, Hiromasa Funato, Kimi Araki & Hiroyasu Nakano. (2022) IκBζ controls IL-17-triggered gene expression program in intestinal epithelial cells that restricts colonization of SFB and prevents Th17-associated pathologies. Mucosal Immunology 15:6, pages 1321-1337.
Crossref
Crossref
Hafiz Ishfaq Ahmad, Abdul Jabbar, Nadia Mushtaq, Zainab Javed, Muhammad Umar Hayyat, Javaria Bashir, Iqra Naseeb, Zain Ul Abideen, Nisar Ahmad & Jinping Chen. (2022) Immune Tolerance vs. Immune Resistance: The Interaction Between Host and Pathogens in Infectious Diseases. Frontiers in Veterinary Science 9.
Crossref
Crossref
Martino Carriero. (2022) Erythrodermic psoriasis and palmoplantar hyperkeratosis successfully treated with secukinumab: a case report. Drug Target Insights 16:1, pages 1-5.
Crossref
Crossref
Marius Piepke, Bettina H. Clausen, Peter Ludewig, Jonas H. Vienhues, Tanja Bedke, Ehsan Javidi, Björn Rissiek, Larissa Jank, Leonie Brockmann, Inga Sandrock, Karoline Degenhardt, Alina Jander, Vanessa Roth, Ines S. Schädlich, Immo Prinz, Richard A. Flavell, Yasushi Kobayashi, Thomas Renné, Christian Gerloff, Samuel Huber, Tim Magnus & Mathias Gelderblom. (2021) Interleukin-10 improves stroke outcome by controlling the detrimental Interleukin-17A response. Journal of Neuroinflammation 18:1.
Crossref
Crossref
Huang Qiong, Ling Han, Nanxue Zhang, Huyan Chen, Kexiang Yan, Zhenghua Zhang, Ying Ma & Jinhua Xu. (2021) Glycyrrhizin improves the pathogenesis of psoriasis partially through IL-17A and the SIRT1-STAT3 axis. BMC Immunology 22:1.
Crossref
Crossref
Chenglin Song, Chenxi Yang, Siwei Meng, Manru Li, Xiao Wang, Yaoxuan Zhu, Lingdong Kong, Wen Lv, Hongzhi Qiao & Yang Sun. (2021) Deciphering the mechanism of Fang-Ji-Di-Huang-Decoction in ameliorating psoriasis-like skin inflammation via the inhibition of IL-23/Th17 cell axis. Journal of Ethnopharmacology 281, pages 114571.
Crossref
Crossref
Yun Fu, Cheng-Han Lee & Ching-Chi Chi. (2021) Association of psoriasis with colorectal cancer. Journal of the American Academy of Dermatology 85:6, pages 1429-1436.
Crossref
Crossref
Chunsheng Zhou, Dongwen Wu, Chetan Jawale, Yang Li, Partha S. Biswas, Mandy J. McGeachy & Sarah L. Gaffen. (2021) Divergent functions of IL-17-family cytokines in DSS colitis: Insights from a naturally-occurring human mutation in IL-17F. Cytokine 148, pages 155715.
Crossref
Crossref
Maria Kościuszko, Anna Popławska-Kita, Przemysław Pawłowski, Danuta Lipińska, Justyna Hryniewicka, Dorota Jankowska, Maria Górska, Adam Krętowski & Janusz Myśliwiec. (2021) Clinical relevance of estimating circulating interleukin-17 and interleukin-23 during methylprednisolone therapy in Graves’ orbitopathy: A preliminary study. Advances in Medical Sciences 66:2, pages 315-320.
Crossref
Crossref
Alex Lipovsky, Peter F. Slivka, Zhi Su, Yibing Wang, Stephanie Paulsboe, Joseph Wetter, Marian T. Namovic, Donna Gauvin, Denise Perron, Stephen B. Gauld, Steven McGaraughty & Eric R. Goedken. (2021) ACT1 Is Required for Murine IL-23–Induced Psoriasiform Inflammation Potentially Independent of E3 Ligase Activity. Journal of Investigative Dermatology 141:7, pages 1772-1779.e6.
Crossref
Crossref
Ahmed Yousaf, Rahul Raiker, Stephen M. Davis, Swapna Gayam & Zachary Zinn. (2020) Association between psoriasis, psoriatic arthritis and gastrointestinal disease. Wiener klinische Wochenschrift 133:11-12, pages 586-593.
Crossref
Crossref
Wenjun Wang, Qiongqiong Xu, Bao Li, Hui Li, Songke Shen, Jing Wu, Huiyao Ge, Hui Zhang, Shirui Chen, Weiwei Chen, Jinping Gao, Huayang Tang, Bo Liang, Xiaodong Zheng & Liangdan Sun. (2021) Proteomic analysis of psoriatic skin lesions in a Chinese population. Journal of Proteomics 240, pages 104207.
Crossref
Crossref
David P. Basile, Md Mahbub Ullah, Jason A. Collet & Purvi Mehrotra. (2021) T helper 17 cells in the pathophysiology of acute and chronic kidney disease. Kidney Research and Clinical Practice 40:1, pages 12-28.
Crossref
Crossref
David P. Basile, Justine M. Abais-Battad & David L. Mattson. (2021) Contribution of Th17 cells to tissue injury in hypertension. Current Opinion in Nephrology & Hypertension 30:2, pages 151-158.
Crossref
Crossref
Gang Bian, Lidan Wang, Qing Xie, Yanping Wang, Haimei Feng, Yunhui Yu, Zijun Chen, Shiping Deng & Yunsen Li. (2020) DGT, a novel heterocyclic diterpenoid, effectively suppresses psoriasis via inhibition of STAT3 phosphorylation. British Journal of Pharmacology.
Crossref
Crossref
Elia Álvarez-Coiradas, Cristian R. Munteanu, Laura Díaz-Sáez, Alejandro Pazos, Kilian V.M. Huber, María Isabel Loza & Eduardo Domínguez. (2020) Discovery of novel immunopharmacological ligands targeting the IL-17 inflammatory pathway. International Immunopharmacology 89, pages 107026.
Crossref
Crossref
A. M. Dadalova, E. A. Vasilenko, R. R. Samigullina & V. I. Mazurov. (2020) Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis. Modern Rheumatology Journal 14:4, pages 165-170.
Crossref
Crossref
Junjue Chen, Xiaohong Liu & Yisheng Zhong. (2020) Interleukin-17A: The Key Cytokine in Neurodegenerative Diseases. Frontiers in Aging Neuroscience 12.
Crossref
Crossref
Christina Lückel, Felix. S. R. Picard & Magdalena Huber. (2020) Tc17 biology and function: Novel concepts. European Journal of Immunology 50:9, pages 1257-1267.
Crossref
Crossref
Fathia M. Khattab & Mai A. Samir. (2019) Measurement of squamous cell carcinoma antigen 2 in lichen planus patients. Journal of Cosmetic Dermatology 19:7, pages 1780-1784.
Crossref
Crossref
Nickisa M. Hodgson & Fatemeh Rajaii. (2019) Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review. Ophthalmology and Therapy 9:1, pages 21-33.
Crossref
Crossref
Gilson Gonçalves dos Santos, Lauriane Delay, Tony L. Yaksh & Maripat Corr. (2020) Neuraxial Cytokines in Pain States. Frontiers in Immunology 10.
Crossref
Crossref
N.A. Savvina, N.P. Sleptsova & I.G. Steshenko. (2020) Experience of using the domestic inhibitor IL (anti-IL-17A) in the treatment of moderate-severe psoriasis. Klinicheskaya dermatologiya i venerologiya 19:5, pages 739.
Crossref
Crossref
Dominika Wcisło‐Dziadecka, Agata Kaźmierczak, Beniamin Grabarek, Martyna Zbiciak‐Nylec & Ligia Brzezińska‐Wcisło. (2019)
Are new variants of psoriasis therapy (
IL
‐17 inhibitors) safe?
. International Journal of Dermatology 58:12, pages 1360-1365.
Crossref
Crossref
Yasmin Hadian, Michelle D. Bagood, Sara E. Dahle, Apra Sood & R. Rivkah Isseroff. (2019) Interleukin-17: Potential Target for Chronic Wounds. Mediators of Inflammation 2019, pages 1-10.
Crossref
Crossref
Purvi Mehrotra, Michael Sturek, Javier A. Neyra & David P. Basile. (2019) Calcium channel Orai1 promotes lymphocyte IL-17 expression and progressive kidney injury. Journal of Clinical Investigation 129:11, pages 4951-4961.
Crossref
Crossref
Qian Yu, Yunlei Tong, Lian Cui, Lingling Zhang, Yu Gong, Hongyue Diao, Fei Gao & Yuling Shi. (2019) Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis. International Immunopharmacology 73, pages 442-450.
Crossref
Crossref
K.A. Papp, M. Gooderham, R. Jenkins, R. Vender, J.C. Szepietowski, T. Wagner, B. Hunt & B. Souberbielle. (2018)
Granulocyte–macrophage colony‐stimulating factor (
GM
‐
CSF
) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐
GM
‐
CSF
monoclonal antibody
. British Journal of Dermatology 180:6, pages 1352-1360.
Crossref
Crossref
Mandy J. McGeachy, Daniel J. Cua & Sarah L. Gaffen. (2019) The IL-17 Family of Cytokines in Health and Disease. Immunity 50:4, pages 892-906.
Crossref
Crossref
Kunal Malik, Helen He, Thy Nhat Huynh, Gary Tran, Kelly Mueller, Kristina Doytcheva, Yael Renert-Yuval, Tali Czarnowicki, Shai Magidi, Margaret Chou, Yeriel D. Estrada, Huei-Chi Wen, Xiangyu Peng, Hui Xu, Xiuzhong Zheng, James G. Krueger, Amy S. Paller & Emma Guttman-Yassky. (2019) Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature. Journal of Allergy and Clinical Immunology 143:2, pages 604-618.
Crossref
Crossref
Andrew Blauvelt & Andrea Chiricozzi. (2018) The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clinical Reviews in Allergy & Immunology 55:3, pages 379-390.
Crossref
Crossref
Yun Fu, Cheng-Han Lee & Ching-Chi Chi. (2018) Association of Psoriasis With Inflammatory Bowel Disease. JAMA Dermatology 154:12, pages 1417.
Crossref
Crossref
L.H. Eaton, R.J. Dearman, I. Kimber & C.E.M. Griffiths. (2018) Keratinocytes derived from late-onset-psoriasis skin do not impair Langerhans cell migration. British Journal of Dermatology 179:5, pages 1208-1209.
Crossref
Crossref
Yael Renert-Yuval & Emma Guttman-Yassky. (2018) Monoclonal antibodies for the treatment of atopic dermatitis. Current Opinion in Allergy & Clinical Immunology 18:4, pages 356-364.
Crossref
Crossref
Claus Zachariae, Kenneth Gordon, Alexandra B. Kimball, Mark Lebwohl, Andrew Blauvelt, Craig Leonardi, Daniel Braun, Missy McKean-Matthews, Russel Burge & Gregory Cameron. (2018) Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. Journal of the American Academy of Dermatology 79:2, pages 294-301.e6.
Crossref
Crossref
Fabio Casciano, Paolo D. Pigatto, Paola Secchiero, Roberto Gambari & Eva Reali. (2018) T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities. Frontiers in Immunology 9.
Crossref
Crossref
L.H. Eaton, K.T. MellodyS.M. Pilkington, R.J. DearmanI. KimberC.E.M. Griffiths. (2018) Impaired Langerhans cell migration in psoriasis is due to an altered keratinocyte phenotype induced by interleukin-17. British Journal of Dermatology 178:6, pages 1364-1372.
Crossref
Crossref
Ziwen Sun, Xiaomin Shi, Yun Wang & Yi Zhao. (2018) Serum Squamous Cell Carcinoma Antigen in Psoriasis: A Potential Quantitative Biomarker for Disease Severity. Dermatology 234:3-4, pages 120-126.
Crossref
Crossref
C. Paul, L. Guenther, H. Torii, H. Sofen, R. Burge, C.Y. Lin, A. Potts Bleakman, L. Mallbris & Y. Poulin. (2017)
Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase
III
trials
. Journal of the European Academy of Dermatology and Venereology 32:1, pages 68-72.
Crossref
Crossref
Emma Guttman-Yassky & James G Krueger. (2017) Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?. Current Opinion in Immunology 48, pages 68-73.
Crossref
Crossref
J. Agustin Cruz, Erin E. Childs, Nilesh Amatya, Abhishek V. Garg, Rudi Beyaert, Lawrence P. Kane, Brian J. Aneskievich, Averil Ma & Sarah L. Gaffen. (2017) IL-17 Signaling Triggers Degradation of the Constitutive NF-κB Inhibitor ABIN-1. ImmunoHorizons 1:7, pages 133-141.
Crossref
Crossref
Robert Bissonnette, Marc Bourcier, Melinda Gooderham, Chih-ho Hong, Ian Landells, Charles Lynde, Kim Papp, Yves Poulin, Ronald Vender & Marni C. Wiseman. (2017) Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. Journal of Cutaneous Medicine and Surgery 21:2_suppl, pages 2S-40S.
Crossref
Crossref
Alexandra Charruyer, Stephen Fong, Giselle G. Vitcov, Samuel Sklar, Leah Tabernik, Monica Taneja, Melinda Caputo, Catherine Soeung, Lili Yue, Yoshi Uchida, Sarah T. Arron, Karen M. Horton, Robert D. Foster, Shigetoshi Sano, Jeffrey P. North & Ruby Ghadially. (2017) Brief Report: Interleukin‐17A‐Dependent Asymmetric Stem Cell Divisions Are Increased in Human Psoriasis: A Mechanism Underlying Benign Hyperproliferation. STEM CELLS 35:8, pages 2001-2007.
Crossref
Crossref
Yael Renert-Yuval & Emma Guttman-Yassky. (2017) Systemic therapies in atopic dermatitis: The pipeline. Clinics in Dermatology 35:4, pages 387-397.
Crossref
Crossref
Yael Renert-Yuval & Emma Guttman-Yassky. (2017) The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm. Advances in Therapy 34:7, pages 1594-1609.
Crossref
Crossref
D. Wu, S.-Y. Hou, S. Zhao, L.-X. Hou, T. Jiao, N.-N. Xu & N. Zhang. (2017) Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials. Journal of the European Academy of Dermatology and Venereology 31:6, pages 992-1003.
Crossref
Crossref
Attia Attia, Abdelrahman Ibrahim Abushouk, Hussien Ahmed, Mohamed Gadelkarim, Ahmed Elgebaly, Zeinab Hassan, Mohamed M. Abdel-Daim & Ahmed Negida. (2017) Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis. Clinical Drug Investigation 37:5, pages 439-451.
Crossref
Crossref
H.T. Chong, G.N. Yang, S. Sidhu, J. Ibbetson, Z. Kopecki & A.J. Cowin. (2017) Reducing Flightless I expression decreases severity of psoriasis in an imiquimod-induced murine model of psoriasiform dermatitis. British Journal of Dermatology 176:3, pages 705-712.
Crossref
Crossref
F. Gómez-García, D. Epstein, B. Isla-Tejera, A. Lorente, A. Vélez García-Nieto & J. Ruano. (2017) Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. British Journal of Dermatology 176:3, pages 594-603.
Crossref
Crossref
Frank Kolbinger, Christian Loesche, Marie-Anne Valentin, Xiaoyu Jiang, Yi Cheng, Philip Jarvis, Thomas Peters, Claudio Calonder, Gerard Bruin, Florine Polus, Birgit Aigner, David M. Lee, Manfred Bodenlenz, Frank Sinner, Thomas Rudolf Pieber & Dhavalkumar D. Patel. (2017) ?-Defensin 2 is a responsive biomarker of IL-17A?driven skin pathology in patients with psoriasis. Journal of Allergy and Clinical Immunology 139:3, pages 923-932.e8.
Crossref
Crossref
Caini Liu, Liang Zhu, Koichi FukudaSuidong Ouyang, Xing Chen, Chenhui WangCun-jin ZhangBradley MartinChunfang GuLuke Qin, Suguna RachakondaMark AronicaJun QinXiaoxia Li. (2017) The flavonoid cyanidin blocks binding of the cytokine interleukin-17A to the IL-17RA subunit to alleviate inflammation in vivo. Science Signaling 10:467.
Crossref
Crossref
Jaehwan KimJames G. Krueger. (2017) Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. Annual Review of Medicine 68:1, pages 255-269.
Crossref
Crossref
Amy S. Paller, Yael Renert-Yuval, Maria Suprun, Hitokazu Esaki, Margeaux Oliva, Thy Nhat Huynh, Benjamin Ungar, Norma Kunjravia, Rivka Friedland, Xiangyu Peng, Xiuzhong Zheng, Yeriel D. Estrada, James G. Krueger, Keith A. Choate, Mayte Suárez-Fariñas & Emma Guttman-Yassky. (2017) An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis. Journal of Allergy and Clinical Immunology 139:1, pages 152-165.
Crossref
Crossref
Rafael Leite Dantas, Dörthe Masemann, Tanja Schied, Vera Bergmeier, Thomas Vogl, Karin Loser, Bent Brachvogel, Georg Varga, Stephan Ludwig & Viktor Wixler. (2016) Macrophage-mediated psoriasis can be suppressed by regulatory T lymphocytes. The Journal of Pathology 240:3, pages 366-377.
Crossref
Crossref
Margeaux Oliva, Yael Renert-Yuval & Emma Guttman-Yassky. (2016) The ‘omics’ revolution: redefining the understanding and treatment of allergic skin diseases. Current Opinion in Allergy & Clinical Immunology 16:5, pages 469-476.
Crossref
Crossref
L.H. EatonR.J. DearmanI. KimberC.E.M. Griffiths. (2016) Interleukin-17 and interleukin-23 regulate Langerhans cell migration. British Journal of Dermatology 175:3, pages 622-624.
Crossref
Crossref
Y. Watanabe, Y. Yamaguchi, N. Komitsu, S. Ohta, Y. Azuma, K. Izuhara & M. Aihara. (2016) Elevation of serum squamous cell carcinoma antigen 2 in patients with psoriasis: associations with disease severity and response to the treatment. British Journal of Dermatology 174:6, pages 1327-1336.
Crossref
Crossref
Yuping Lai & Chen Dong. (2016) Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. International Immunology 28:4, pages 181-188.
Crossref
Crossref
Marcel C. Pasch. (2016) Nail Psoriasis: A Review of Treatment Options. Drugs 76:6, pages 675-705.
Crossref
Crossref
Juan Ruano, Mayte Suárez-Fariñas, Avner Shemer, Margeaux Oliva, Emma Guttman-Yassky & James G. Krueger. (2016) Molecular and Cellular Profiling of Scalp Psoriasis Reveals Differences and Similarities Compared to Skin Psoriasis. PLOS ONE 11:2, pages e0148450.
Crossref
Crossref
I. E. Deckers & E. P. Prens. (2015) An Update on Medical Treatment Options for Hidradenitis Suppurativa. Drugs 76:2, pages 215-229.
Crossref
Crossref
Melodie S. Young & Kristine J. Kucera. (2016) Mechanistic Insights Into Today’s (and Tomorrow’s) Treatments for Moderate-to-Severe Psoriasis. Journal of the Dermatology Nurses' Association 8:1, pages 29-43.
Crossref
Crossref
Jaehwan Kim, Chil-Hwan Oh, Jiehyun Jeon, Yoosang Baek, Jaewoo Ahn, Dong Joo Kim, Hyun-Soo Lee, Joel Correa da Rosa, Mayte Suárez-Fariñas, Michelle A. Lowes & James G. Krueger. (2016) Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets. Journal of Investigative Dermatology 136:1, pages 161-172.
Crossref
Crossref
Yuping Lai & Chen Dong. 2016. Encyclopedia of Immunobiology. Encyclopedia of Immunobiology
534
543
.
Srilakshmi M. Sharma & James T. Rosenbaum. 2016. Intraocular Inflammation. Intraocular Inflammation
713
718
.
A. Turrión Nieves, R. Martín Holguera, A. Sánchez Atrio, M.L. Romero Bogado & M. Álvarez de Mon Soto. (2015) Tratamientos biológicos en enfermedades reumatológicas y autoinmunes sistémicas. Medicine - Programa de Formación Médica Continuada Acreditado 11:92, pages 5496-5509.
Crossref
Crossref
Morton Scheinberg. (2015) A new era in psoriasis and psoriatic arthritis therapy: new mechanisms of action and the introduction of biogeneric drugs. Revista Brasileira de Reumatologia (English Edition) 55:6, pages 469-470.
Crossref
Crossref
Morton Scheinberg. (2015) Uma nova era na terapia em psoríase e artrite psoriática: novos mecanismos de ação e a introdução de biossimilares. Revista Brasileira de Reumatologia 55:6, pages 469-470.
Crossref
Crossref
Ramin Fathi & April Wang Armstrong. (2015) The Role of Biologic Therapies in Dermatology. Medical Clinics of North America 99:6, pages 1183-1194.
Crossref
Crossref
Ana Batalla, Eliecer Coto, Leire González-Lara, Daniel González-Fernández, Juan Gómez, Tamara F. Aranguren, Rubén Queiro, Jorge Santos-Juanes, Carlos López-Larrea & Pablo Coto-Segura. (2015) Association between single nucleotide polymorphisms IL17RA rs4819554 and IL17E rs79877597 and Psoriasis in a Spanish cohort.. Journal of Dermatological Science 80:2, pages 111-115.
Crossref
Crossref
Jamie L. Harden, James G. Krueger & Anne M. Bowcock. (2015) The immunogenetics of Psoriasis: A comprehensive review. Journal of Autoimmunity 64, pages 66-73.
Crossref
Crossref
Camille Zenobia & George Hajishengallis. (2015) Basic biology and role of interleukin-17 in immunity and inflammation. Periodontology 2000 69:1, pages 142-159.
Crossref
Crossref
Yan Chen, Tian Qian, Dongmei Zhang, Heng Yan & Fei Hao. (2015) Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis. Immunotherapy 7:9, pages 1023-1037.
Crossref
Crossref
Marc Feldmann & Ravinder N. Maini. (2015) Perspectives From Masters in Rheumatology and Autoimmunity: Can We Get Closer to a Cure for Rheumatoid Arthritis?. Arthritis & Rheumatology 67:9, pages 2283-2291.
Crossref
Crossref
Paul R. Mangan, Linhui Julie Su, Victoria Jenny, Andrea L. Tatum, Caryn Picarillo, Stacey Skala, Noah Ditto, Zheng Lin, XiaoXia Yang, Pete Z. Cotter, David J. Shuster, Yunling Song, Virna Borowski, Rochelle L. Thomas, Elizabeth M. Heimrich, Brigitte Devaux, Ruchira Das Gupta, Irvith Carvajal, Kim W. McIntyre, Jenny Xie, Qihong Zhao, Mary Struthers & Luisa M. Salter-Cid. (2015) Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of Autoimmunity. Journal of Pharmacology and Experimental Therapeutics 354:2, pages 152-165.
Crossref
Crossref
Sayaka Shibata, Yayoi Tada, Carren Sy Hau, Aya Mitsui, Masahiro Kamata, Yoshihide Asano, Makoto Sugaya, Takafumi Kadono, Yosuke Masamoto, Mineo Kurokawa, Toshimasa Yamauchi, Naoto Kubota, Takashi Kadowaki & Shinichi Sato. (2015) Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells. Nature Communications 6:1.
Crossref
Crossref
Anthony A. Gaspari & Stephen Tyring. (2015)
New and emerging biologic therapies for moderate‐to‐severe plaque psoriasis: mechanistic rationales and recent clinical data for
IL
‐17 and
IL
‐23 inhibitors
. Dermatologic Therapy 28:4, pages 179-193.
Crossref
Crossref
Erik Lubberts. (2015) The IL-23–IL-17 axis in inflammatory arthritis. Nature Reviews Rheumatology 11:7, pages 415-429.
Crossref
Crossref
Elizabeth Z. Welch, Kathryn L. Anderson & Steven R. Feldman. (2015) Interleukin 17 deficiency and implications in cutaneous and systemic diseases. Journal of Dermatology & Dermatologic Surgery 19:2, pages 73-79.
Crossref
Crossref
Natasa Isailovic, Kenji Daigo, Alberto Mantovani & Carlo Selmi. (2015) Interleukin-17 and innate immunity in infections and chronic inflammation. Journal of Autoimmunity 60, pages 1-11.
Crossref
Crossref
Yasaman Mansouri & Emma Guttman-Yassky. (2015) Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics. Journal of Clinical Medicine 4:5, pages 858-873.
Crossref
Crossref
T. Torres & L. Puig. (2015) Treatment goals for psoriasis: Should PASI 90 become the standard of care?. Actas Dermo-Sifiliográficas (English Edition) 106:3, pages 155-157.
Crossref
Crossref
T. Torres & L. Puig. (2015) Treatment goals for psoriasis: Should PASI 90 become the standard of care?. Actas Dermo-Sifiliográficas 106:3, pages 155-157.
Crossref
Crossref
Shivani Felicia Chandrakumar & Jensen Yeung. (2015) Interleukin-17 Antagonists in the Treatment of Psoriasis. Journal of Cutaneous Medicine and Surgery 19:2, pages 109-114.
Crossref
Crossref
April ZhangCatherine NguyenJohn Y.M. Koo. (2018) Stress and Psoriasis: Review of Pathophysiology with New Data on Immunological Mechanisms. Psoriasis Forum 21a:1, pages 53-59.
Crossref
Crossref
Shinji Noda, James G. Krueger & Emma Guttman-Yassky. (2015) The translational revolution and use of biologics in patients with inflammatory skin diseases. Journal of Allergy and Clinical Immunology 135:2, pages 324-336.
Crossref
Crossref
Jennifer C. Cather & Jeffrey J. Crowley. (2014) Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis. American Journal of Clinical Dermatology 15:6, pages 467-478.
Crossref
Crossref
Romy R. M. C. Keijsers, Irma Joosten, Piet E. J van Erp, Hans J. P. M. Koenen & Peter. C. M. van de Kerkhof. (2014)
Cellular sources of
IL
‐17 in psoriasis: a paradigm shift?
. Experimental Dermatology 23:11, pages 799-803.
Crossref
Crossref
Wendy Cantrell & Rhonda Kaler. (2014) Biologic Agents for Moderate-to-Severe Plaque Psoriasis. Journal of the Dermatology Nurses' Association 6:5S, pages S12-S30.
Crossref
Crossref
Sarah L. Gaffen, Renu Jain, Abhishek V. Garg & Daniel J. Cua. (2014) The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing. Nature Reviews Immunology 14:9, pages 585-600.
Crossref
Crossref
Wendy Cantrell & Rhonda Kaler. (2014) Biologic Agents for Moderate-to-Severe Plaque Psoriasis. Journal of the Dermatology Nurses' Association 6:4, pages 178-196.
Crossref
Crossref
Paolo Gisondi, Camilla Dalle Vedove & Giampiero Girolomoni. (2014) Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy. Dermatology and Therapy 4:1, pages 1-9.
Crossref
Crossref
Ilja Striz, Eva Brabcova, Libor Kolesar & Alena Sekerkova. (2014) Cytokine networking of innate immunity cells: a potential target of therapy. Clinical Science 126:9, pages 593-612.
Crossref
Crossref
Shoubao Ma, Qiao Cheng, Yifeng Cai, Huanle Gong, Yan Wu, Xiao Yu, Liyun Shi, Depei Wu, Chen Dong & Haiyan Liu. (2014) IL-17A Produced by γδ T Cells Promotes Tumor Growth in Hepatocellular Carcinoma. Cancer Research 74:7, pages 1969-1982.
Crossref
Crossref
Andrea Saggini, Sergio Chimenti & Andrea Chiricozzi. (2014) IL-6 as a Druggable Target in Psoriasis: Focus on Pustular Variants. Journal of Immunology Research 2014, pages 1-10.
Crossref
Crossref